195 related articles for article (PubMed ID: 18697940)
21. Pax5: a master regulator of B cell development and leukemogenesis.
Medvedovic J; Ebert A; Tagoh H; Busslinger M
Adv Immunol; 2011; 111():179-206. PubMed ID: 21970955
[TBL] [Abstract][Full Text] [Related]
22. PAX5 deletion is common and concurrently occurs with CDKN2A deletion in B-lineage acute lymphoblastic leukemia.
Kim M; Choi JE; She CJ; Hwang SM; Shin HY; Ahn HS; Yoon SS; Kim BK; Park MH; Lee DS
Blood Cells Mol Dis; 2011 Jun; 47(1):62-6. PubMed ID: 21549623
[TBL] [Abstract][Full Text] [Related]
23. Oncogenic role of Pax5 in the T-lymphoid lineage upon ectopic expression from the immunoglobulin heavy-chain locus.
Souabni A; Jochum W; Busslinger M
Blood; 2007 Jan; 109(1):281-9. PubMed ID: 16968900
[TBL] [Abstract][Full Text] [Related]
24. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia.
Mullighan CG; Goorha S; Radtke I; Miller CB; Coustan-Smith E; Dalton JD; Girtman K; Mathew S; Ma J; Pounds SB; Su X; Pui CH; Relling MV; Evans WE; Shurtleff SA; Downing JR
Nature; 2007 Apr; 446(7137):758-64. PubMed ID: 17344859
[TBL] [Abstract][Full Text] [Related]
25. PAX5 is part of a functional transcription factor network targeted in lymphoid leukemia.
Okuyama K; Strid T; Kuruvilla J; Somasundaram R; Cristobal S; Smith E; Prasad M; Fioretos T; Lilljebjörn H; Soneji S; Lang S; Ungerbäck J; Sigvardsson M
PLoS Genet; 2019 Aug; 15(8):e1008280. PubMed ID: 31381561
[TBL] [Abstract][Full Text] [Related]
26. PAX immunoreactivity identifies alveolar rhabdomyosarcoma.
Sullivan LM; Atkins KA; LeGallo RD
Am J Surg Pathol; 2009 May; 33(5):775-80. PubMed ID: 19145202
[TBL] [Abstract][Full Text] [Related]
27. PAX5 mutations occur frequently in adult B-cell progenitor acute lymphoblastic leukemia and PAX5 haploinsufficiency is associated with BCR-ABL1 and TCF3-PBX1 fusion genes: a GRAALL study.
Familiades J; Bousquet M; Lafage-Pochitaloff M; Béné MC; Beldjord K; De Vos J; Dastugue N; Coyaud E; Struski S; Quelen C; Prade-Houdellier N; Dobbelstein S; Cayuela JM; Soulier J; Grardel N; Preudhomme C; Cavé H; Blanchet O; Lhéritier V; Delannoy A; Chalandon Y; Ifrah N; Pigneux A; Brousset P; Macintyre EA; Huguet F; Dombret H; Broccardo C; Delabesse E
Leukemia; 2009 Nov; 23(11):1989-98. PubMed ID: 19587702
[TBL] [Abstract][Full Text] [Related]
28. Integration of genomic and gene expression data of childhood ALL without known aberrations identifies subgroups with specific genetic hallmarks.
Bungaro S; Dell'Orto MC; Zangrando A; Basso D; Gorletta T; Lo Nigro L; Leszl A; Young BD; Basso G; Bicciato S; Biondi A; te Kronnie G; Cazzaniga G
Genes Chromosomes Cancer; 2009 Jan; 48(1):22-38. PubMed ID: 18803328
[TBL] [Abstract][Full Text] [Related]
29. PAX5-AUTS2 fusion resulting from t(7;9)(q11.2;p13.2) can now be classified as recurrent in B cell acute lymphoblastic leukemia.
Coyaud E; Struski S; Dastugue N; Brousset P; Broccardo C; Bradtke J
Leuk Res; 2010 Dec; 34(12):e323-5. PubMed ID: 20723977
[No Abstract] [Full Text] [Related]
30. The Genomic Landscape of PAX5, IKZF1, and CDKN2A/B Alterations in B-Cell Precursor Acute Lymphoblastic Leukemia.
Ou Z; Sherer M; Casey J; Bakos HA; Vitullo K; Hu J; Friehling E; Gollin SM; Surti U; Yatsenko SA
Cytogenet Genome Res; 2016; 150(3-4):242-252. PubMed ID: 28214896
[TBL] [Abstract][Full Text] [Related]
31. The correlation between Pax5 deletion and patients survival in Iranian children with precursor B-cell acute lymphocytic leukemia.
Moafi A; Zojaji A; Salehi R; Najafi Dorcheh S; Rahgozar S
Cell Mol Biol (Noisy-le-grand); 2017 Aug; 63(8):19-22. PubMed ID: 28886309
[TBL] [Abstract][Full Text] [Related]
32. Pax5 loss imposes a reversible differentiation block in B-progenitor acute lymphoblastic leukemia.
Liu GJ; Cimmino L; Jude JG; Hu Y; Witkowski MT; McKenzie MD; Kartal-Kaess M; Best SA; Tuohey L; Liao Y; Shi W; Mullighan CG; Farrar MA; Nutt SL; Smyth GK; Zuber J; Dickins RA
Genes Dev; 2014 Jun; 28(12):1337-50. PubMed ID: 24939936
[TBL] [Abstract][Full Text] [Related]
33. ETV6-AML1 translocation breakpoints cluster near a purine/pyrimidine repeat region in the ETV6 gene.
Thandla SP; Ploski JE; Raza-Egilmez SZ; Chhalliyil PP; Block AW; de Jong PJ; Aplan PD
Blood; 1999 Jan; 93(1):293-9. PubMed ID: 9864173
[TBL] [Abstract][Full Text] [Related]
34. LCK over-expression drives STAT5 oncogenic signaling in PAX5 translocated BCP-ALL patients.
Cazzaniga V; Bugarin C; Bardini M; Giordan M; te Kronnie G; Basso G; Biondi A; Fazio G; Cazzaniga G
Oncotarget; 2015 Jan; 6(3):1569-81. PubMed ID: 25595912
[TBL] [Abstract][Full Text] [Related]
35. PAX5/ETV6 fusion defines cytogenetic entity dic(9;12)(p13;p13).
Strehl S; König M; Dworzak MN; Kalwak K; Haas OA
Leukemia; 2003 Jun; 17(6):1121-3. PubMed ID: 12764378
[TBL] [Abstract][Full Text] [Related]
36. PAX5 is a tumor suppressor in mouse mutagenesis models of acute lymphoblastic leukemia.
Dang J; Wei L; de Ridder J; Su X; Rust AG; Roberts KG; Payne-Turner D; Cheng J; Ma J; Qu C; Wu G; Song G; Huether RG; Schulman B; Janke L; Zhang J; Downing JR; van der Weyden L; Adams DJ; Mullighan CG
Blood; 2015 Jun; 125(23):3609-17. PubMed ID: 25855603
[TBL] [Abstract][Full Text] [Related]
37. Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia.
Nebral K; Denk D; Attarbaschi A; König M; Mann G; Haas OA; Strehl S
Leukemia; 2009 Jan; 23(1):134-43. PubMed ID: 19020546
[TBL] [Abstract][Full Text] [Related]
38. Expression of the PAX5/BSAP transcription factor in haematological tumour cells and further molecular characterization of the t(9;14)(p13;q32) translocation in B-cell non-Hodgkin's lymphoma.
Hamada T; Yonetani N; Ueda C; Maesako Y; Akasaka H; Akasaka T; Ohno H; Kawakami K; Amakawa R; Okuma M
Br J Haematol; 1998 Aug; 102(3):691-700. PubMed ID: 9722295
[TBL] [Abstract][Full Text] [Related]
39. PAX5/TEL acts as a transcriptional repressor causing down-modulation of CD19, enhances migration to CXCL12, and confers survival advantage in pre-BI cells.
Fazio G; Palmi C; Rolink A; Biondi A; Cazzaniga G
Cancer Res; 2008 Jan; 68(1):181-9. PubMed ID: 18172310
[TBL] [Abstract][Full Text] [Related]
40. Diffuse large B-cell lymphoma carrying t(9;14)(p13;q32)/PAX5-immunoglobulin heavy chain gene is characterized by nuclear positivity of MUM1 and PAX5 by immunohistochemistry.
Ohno H; Nakagawa M; Kishimori C; Fukutsuka K; Maekawa F; Takeoka K; Hayashida M; Sakamoto S; Akasaka T; Honjo G
Hematol Oncol; 2020 Apr; 38(2):171-180. PubMed ID: 31955451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
